Physician profile
Nitin Khosla
NPI 1841368982
$40,531.53
in general payments reported to CMS, 2019-2025
19 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,604 · 2020: $4,049 · 2021: $15.51 · 2022: $13K · 2023: $11K · 2024: $6,022 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,625 · Consulting Fee: $4,141 · Travel and Lodging: $2,810 · Food and Beverage: $580 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,624.90 |
| Consulting Fee | $4,141.00 |
| Travel and Lodging | $2,809.95 |
| Food and Beverage | $580.24 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $39,395.13 | 2019-2025 | Jynarque, Tolvaptan, Voyxact |
| Fresenius USA Marketing, INC. | $158.83 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $125.76 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $122.37 | 2019 | |
| Opko Pharmaceuticals, LLC | $112.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $102.00 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $91.81 | 2020-2023 | Acthar |
| Amgen INC. | $84.58 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $66.18 | 2019 | |
| Vantive US Healthcare LLC | $63.07 | 2025 | Renal - Acute |
| Travere Therapeutics, INC. | $45.09 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $34.83 | 2019-2020 | |
| Glaxosmithkline, LLC. | $28.85 | 2024 | Benlysta |
| Calliditas Therapeutics US INC. | $21.10 | 2023 | Tarpeyo |
| Ardelyx, INC. | $18.37 | 2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.50 | 2025 | Wegovy |
| Horizon Therapeutics Plc | $16.01 | 2019 | |
| Abbvie INC. | $15.51 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Khosla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.